Virological and immunological outcomes in HIV-1-infected Chinese patients treated with a combination of Efavirenz and Indinavir for 48 weeks  被引量:4

Virological and immunological outcomes in HIV-1-infected Chinese patients treated with a combination of Efavirenz and Indinavir for 48 weeks

在线阅读下载全文

作  者:李莉 魏飞力 梅珊 冯鑫 姚均 金侠 曹韵贞 

机构地区:[1]National Center for AIDS Prevention and Control [2]Department of Infections Diaseases Beijing Ditan Hospital [3]Department of Infectious Diseases, Rochester University Medical Center,Rochester

出  处:《Chinese Medical Journal》2004年第3期347-352,共6页中华医学杂志(英文版)

摘  要:Background The incidence of HIV-1-related infection d iseases and the mortality of AIDS have dramatically decreased since highly activ e antiretroviral therapy began to be used clinically in China in 1999. And we in itiated a second clinical trial using a combination of Efavirenz and Indinavir to observe the effects of the immunoreaction.Methods Twenty patients with laboratory-confirmed chronic HIV-1 infection were recruited. Blood samples were collected initially and during the weeks after initiation of treatment. Within 48 hours of blood sampling, peripheral blood plasma and mononuclear cells were separated using routine methods. HIV-1 viral load was measured in thawed plasma samples. Within 48 hours of peripheral blood sampling, CD4 + and CD8 + T cell subsets were enumerated.Results The drug regimen was efficient in reducing HIV-1 plasma viral load and increasing total CD4 + T cell counts. The percentage of CD4 + and CD8 + T cel l subsets expressing CD38 and HLA-DR activation markers was positively correlated with plasma viral load and tended to normalize.Conclusions The combination of Efavirenz and Indinavir was generally well tolerated and efficient at reducing HIV-1 RNA. Furthermore, the treatment improved the immunological function.Background The incidence of HIV-1-related infection d iseases and the mortality of AIDS have dramatically decreased since highly activ e antiretroviral therapy began to be used clinically in China in 1999. And we in itiated a second clinical trial using a combination of Efavirenz and Indinavir to observe the effects of the immunoreaction.Methods Twenty patients with laboratory-confirmed chronic HIV-1 infection were recruited. Blood samples were collected initially and during the weeks after initiation of treatment. Within 48 hours of blood sampling, peripheral blood plasma and mononuclear cells were separated using routine methods. HIV-1 viral load was measured in thawed plasma samples. Within 48 hours of peripheral blood sampling, CD4 + and CD8 + T cell subsets were enumerated.Results The drug regimen was efficient in reducing HIV-1 plasma viral load and increasing total CD4 + T cell counts. The percentage of CD4 + and CD8 + T cel l subsets expressing CD38 and HLA-DR activation markers was positively correlated with plasma viral load and tended to normalize.Conclusions The combination of Efavirenz and Indinavir was generally well tolerated and efficient at reducing HIV-1 RNA. Furthermore, the treatment improved the immunological function.

关 键 词:HIV/AIDS viral load CD4  + T cell counts activation markers 

分 类 号:R512.91[医药卫生—内科学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象